河北大学英文网

Academic News: The Biomedical Materials Team at the School of Basic Medical Sciences, Hebei University, has made important research progress in the field of anti-tumor therapy

Recently, the Biomedical Materials Team from the School of Basic Medical Sciences at Hebei University achieved a significant breakthrough in the field of anti-tumor therapy. The related research findings were published in the top international journal Advanced Functional Materials (2026, e31598, IF=19) under the title “Dual-Pathway Pyroptosis Synergistically Triggered by ZIF-90 and Photothermal Boosting of Multienzyme Activity for Enhanced Breast Cancer Immunotherapy and Lung Metastasis Suppression.” This paper lists Hebei University as the primary affiliation, with Liu Wenjia, a doctoral student from the university’s State Key Laboratory of New Pharmaceutical Preparations and Excipients, as the first author, and Professor Zhou Guoqiang from the School of Basic Medical Sciences, along with Associate Researcher Ge Kun from the School of Chemistry and Materials Science and the State Key Laboratory of New Pharmaceutical Preparations and Excipients, as the co-corresponding authors.

Breast cancer is one of the malignant tumors with the highest incidence rate among women globally. Its low immunogenicity and the immunosuppressive tumor microenvironment severely limit the efficacy of conventional clinical treatments. To address this challenge, the research team ingeniously designed an intelligent nanoreactor: CeO₂:Mn/ZIF-90/ABTS (abbreviated as CMZA). Within the tumor microenvironment, this reactor releases Zn²⁺ to induce cancer cell pyroptosis, awakening the body’s anti-tumor immunity. Concurrently, the CM nanozyme regulates reactive oxygen species homeostasis and synergizes with the photothermal effect of ABTS to further deplete glutathione and amplify oxidative stress. This strategy achieves a multi-pronged synergy of “photothermal enhancement - multi-enzyme cascade - pyroptosis induction,” significantly improving the efficacy of breast cancer immunotherapy and offering an innovative interdisciplinary solution for clinical cancer treatment.

This research serves as a quintessential example of the deep integration of medicine, chemistry, and materials science, vividly demonstrating the accomplishments of the Interdisciplinary Center at Hebei University. Guided by the overarching goal of “serving national strategies, supporting regional development, and empowering ‘Double First-Class’ construction,” the center is dedicated to building a cross-disciplinary innovation platform. Addressing critical clinical needs, the research team combined a profound understanding of tumor mechanisms from basic medicine with advanced design concepts from the field of chemical materials, fully showcasing the innovative advantages of multidisciplinary integration. The publication of this work not only reflects the original innovation capability of the university's State Key Laboratory of New Pharmaceutical Preparations and Excipients in cutting-edge interdisciplinary fields but also provides robust support for the university's actively promoted construction of the “Biomedicine and Disease Diagnosis & Therapy Interdisciplinary Research Institute.”

In recent years, the Biomedical Materials research team has focused on areas such as the design of anti-tumor nanomedicines and the development and application of bone repair materials. They have published a series of innovative results in internationally renowned journals, including Advanced Functional Materials (2026, 0:e31598), Advanced Healthcare Materials (2024, 2402216), and Regenerative Biomaterials (2025, 12, rbaf066). The aforementioned research was supported by grants from the National Natural Science Foundation of China, the Natural Science Foundation for Distinguished Young Scholars of Hebei Province, the Central Government Guided Local Science and Technology Development Fund Projects, and the Hebei University Multidisciplinary Interdisciplinary Research Program.